ADMA Biologics

ADMA NASDAQ
4.435
-0.265
-5.64%
Opening 15:33 05/24 EDT
Open
4.730
Prev Close
4.700
High
4.730
Low
4.370
Volume
787.41K
Avg Vol (3M)
1.24M
52 Week High
6.96
52 Week Low
2.080
% Turnover
1.74%
Market Cap
200.98M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.
MORE >

Recently

Name
Price
%Change